Literature DB >> 36244021

Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Ronglin Gao1, Zhenzhen Wu1, Xianghuai Xu2, Jincheng Pu1, Shengnan Pan1, Youwei Zhang1, Shuqi Zhuang1, Lufei Yang1, Yuanyuan Liang1, Jiamin Song1, Jianping Tang3, Xuan Wang4.   

Abstract

To identify potential predictors by assessing adverse outcomes in ANCA-associated vasculitis (AAV) patients. Eighty-nine untreated AAV patients were followed up to January 31, 2022, death, or loss of follow-up. Clinical characteristics, laboratory tests, treatment, and progress were collected, and disease activity was evaluated via Birmingham Vasculitis Activity Score (BVAS). We determined risk factors of high-risk events, defined as developing tumors, renal replacement therapy (RRT), and death. Patients and renal survivals were computed by the Kaplan-Meier curve analysis. Cox regression analysis was performed for assessing variables for predicting death. During 267 person-years follow-up, 46 patients occurred high-risk events, including 20 patients receiving RRT, 12 patients developing tumors, and 29 patients who died mostly from organ failure and infection. Decreased estimated glomerular filtration rate (eGFR) (P < 0.001) and complement 3 levels (P = 0.019) were associated with high-risk events. Patients with lower serum potassium tended to develop tumors (P = 0.033); with higher BVAS (HR = 1.290, 95%CI 1.075-1.549, P = 0.006) and lower eGFR (HR = 0.782, 95%CI 0.680-0.901, P = 0.001) were more likely to undergo RRT. Patients with cardio and renal involvement exhibited a lower frequency of renal survival and all-cause mortality. Through multivariate COX analysis, age (HR = 1.016, 95%CI 1.016-1.105, P = 0.006) and eGFR (HR = 0.982, 95%CI 0.968-0.997, P = 0.018) predicted death in AAV, separately. The BVAS and eGFR could be a great prognosticator for RRT, while age and eGFR can independently predict the death. Serum potassium level and immunoglobulins should be focused on their predictor value in development of cancer and renal outcomes in AAV patients.
© 2022. The Author(s).

Entities:  

Keywords:  ANCA-associated vasculitis; Mortality; Renal replace therapy; Risk factors/ predictors; Tumor

Year:  2022        PMID: 36244021     DOI: 10.1007/s10238-022-00915-z

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  53 in total

1.  Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China.

Authors:  Dong-Yuan Chang; Zhi-Ying Li; Min Chen; Ming-Hui Zhao
Journal:  Semin Arthritis Rheum       Date:  2018-05-09       Impact factor: 5.532

2.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

Authors:  A S Fauci; P Katz; B F Haynes; S M Wolff
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

3.  Long-term patient survival in ANCA-associated vasculitis.

Authors:  Oliver Flossmann; Annelies Berden; Kirsten de Groot; Chris Hagen; Lorraine Harper; Caroline Heijl; Peter Höglund; David Jayne; Raashid Luqmani; Alfred Mahr; Chetan Mukhtyar; Charles Pusey; Niels Rasmussen; Coen Stegeman; Michael Walsh; Kerstin Westman
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

Review 4.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

5.  The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study.

Authors:  Sang Tae Choi; Song Vogue Ahn; Poong Hoon Lee; Chang Mo Moon
Journal:  Semin Arthritis Rheum       Date:  2021-04-01       Impact factor: 5.532

Review 6.  ANCA-associated vasculitis.

Authors:  A Richard Kitching; Hans-Joachim Anders; Neil Basu; Elisabeth Brouwer; Jennifer Gordon; David R Jayne; Joyce Kullman; Paul A Lyons; Peter A Merkel; Caroline O S Savage; Ulrich Specks; Renate Kain
Journal:  Nat Rev Dis Primers       Date:  2020-08-27       Impact factor: 52.329

Review 7.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Authors:  A S Fauci; B F Haynes; P Katz; S M Wolff
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

8.  Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.

Authors:  Anoek A E de Joode; Jan Stephan F Sanders; Coen A Stegeman
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 8.237

9.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Authors:  Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2013-11-15       Impact factor: 19.103

Review 10.  B Lineage Cells in ANCA-Associated Vasculitis.

Authors:  Ana Merino-Vico; Jan Piet van Hamburg; Sander W Tas
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.